CLAIMS:

1. A process for preparing of an extract from the plant *Murraya koenigii*, useful in the treatment of asthma, said process comprising the steps of pulverising plant materials obtained from plant *Murraya koenigii*, extracting the plant material with a solvent at ambient temperature, concentrating the extract by filtering and evaporating it under reduced pressure and lyophilizing the concentrate to obtain a lyophilized extract containing active principles of the plant *Murraya koenigii*.
2. A process as claimed in claim 1 wherein the plant materials are obtained from plant parts of *Murraya koenigii* selected from garden fresh leaves or leaves dried under shade.
3. A process as claimed in claim 1 wherein the leaves are pulverized by conventional methods to get homogenized leaves.
4. A process as claimed in claim 1 wherein the plant materials are extracted with solvents selected from hydrocarbon solvents, chlorinated solvents, ester solvents, ketonic solvents, alcohols, water and buffers.
5. A process as claimed in claim 4 wherein the solvents are selected from the group consisting of petroleum ether (BP 40 – 60°C), petroleum ether (60°C - 80°C), benzene, pentane, hexane, chloroform, dichloromethane, carbon tetrachloride, diethyl ether, tetrahydrofuran, dioxane, acetone, cyclopentanone, ethyl acetate, ethyl formate, methanol, ethanol, n-butanol, water and buffers.
6. A process as claimed in claim 1 wherein the concentration of the extract is effected by filtering and evaporating the solvents under reduced pressure at a temperature range of 20°C – 80°C preferably at ambient temperature and lyophilizing the concentrate by conventional methods to obtain mixtures of the active factors.
7. A process as claimed in claim 1, where in the extract obtained from the plant *Murraya koenigii* comprises active principles which dark colored solids soluble in dimethylsulfoxide.
8. A process as claimed in claim 1, wherein the active principles obtained from the plant *Murraya koenigii* are biocompatible and non-toxic in nature.
9. A process as claimed in claim 1, wherein the pharmaceutical composition is used for inhibition of arachidonic acid oxidation.

10. A process as claimed in claim 1, wherein the active principles have R_f values 0.73, 0.60, 034 and 0.14 in chloroform and methanol in the ratio 19:1 and R_f values 0.60, 0.38, 024 and 0.15 in the chloroform.

11. A process as claimed in claim 1 wherein the active principles have four peak with retention time 3.37, 3.49, 4.0 and 5.69 in methanol as solvent at 254nm.

12. A process as claimed in claim 1 wherein the extraction process is carried out for a period ranging from 1 – 120 hrs, preferably between 12 – 16 hrs.

13. Pharmaceutical composition useful in the treatment of asthma, said composition comprising an effective amount of extract obtained from the plant *Murraya koenigii* together with, or optionally associated with a pharmaceutically acceptable additive.

14. A composition as claimed in claim 13 wherein the additives comprise powder or extracts of plants selected from *M. paniculate Linn*, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A.vasica Nees*, *E hirta*, and *M. koinegii*.

15. A composition as claimed in claim 13 wherein the additives are present in the range of 80-100 mg of *M. paniculate Linn*, 40-60 mg of *H. abelmoschus*, 38-62 mg of *T. ammi*, 7-13 mg of *S. aromaticum*, 85 - 115 mg of *A.vasica Nees* and 90-110 mg of *E hirta*.

16. A composition as claimed in claim 13 comprising :

M. paniculata Linn. Syn. M exotica (KAMINI)	90mg
H. abelmoschus (JOWAN)	50mg
T. ammi (LAVANGA)	50mg
S. aromaticum (BASAK)	10mg
A.vasica Nees (PUSITOA)	100mg
E.hirta	100mg
M. koinegii (Suravi Neem)	100mg

17. A composition as claimed in claim 13 wherein the extract of the plant *M. koinegii* is present in the range of 87-105 mg per dose.

18. A composition as claimed in claim 13 wherein the additives are preferably present in an amount 90 mg of *M. paniculate Linn*, 50 mg of *H. abelmoschus*, 50 mg of *T. ammi*, 10 mg of *S. aromaticum*, 100 mg of *A.vasica Nees*, 100 mg of *E hirta*, and 100 mg of *M. koinegii*. per dose.

19. A composition as claimed in claim 13 wherein the extract of the plant *M. koinegii* comprises active principles which are dark colored solids, soluble in dimethylsulfoxide.

20. A composition as claimed in claim 13 wherein the active principles have R_f values 0.73, 0.60, 034 and 0.14 in chloroform and methanol in the ratio 19:1 and R_f values 0.60, 0.38, 024 and 0.15 in the chloroform.

21. A composition as claimed in claim 13 having four peak with retention time 3.37, 3.49, 4.0 and 5.69 in methanol as solvent at 254nm.

22. A composition as claimed in claim 13 wherein the active principles obtained from the plant *M. koinegii* exhibit antioxidant property i.e. O_2 inhibition.

23. A method for the treatment of asthma, said method comprising the steps of administering an effective amount of the composition as claimed in claim 13 to a subject in need thereof,

24. A method as claimed in claim 23 wherein the lyophilized extract obtained from *Murraya Koenigii* is administered along with other conventional additives for the treatment of asthma.

25. A method as claimed in claim 23 wherein the mode of administration is oral for the treatment of mild or acute asthma.

26. A method as claimed in claim 23 wherein the dosage level of the composition is in between 325-600 mg twice daily for the period ranging from 3 to 30 days.

27. A method as claimed in claim 23 wherein the dosage level is in between 325-600 mg twice daily for the period ranging from 3 to 15 days for mild asthmatic condition, and 15 – 30 days for acute asthmatic condition.

28. A method as claimed in claim 23, wherein the additives are selected from *M. paniculate Linn*, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A.vasica Nees*, *E hirta*, and *M. koinegii*.

29. A method as claimed in claim 23, where in the additives are present in a range of 80-100 mg of *M. paniculate Linn*, 40-60 mg of *H. abelmoschus*, 38-62 mg of *T. ammi*, 7-13 mg of *S. aromaticum*, 85-115 mg of *A.vasica Nees*, 90-110 mg of *E hirta*, and 87-105 mg of *M. koinegii*. per dose.

30. A method as claimed in claim 23, wherein the additives are preferably present in an amount 90 mg of *M. paniculate Linn*, 50 mg of *H. abelmoschus*, 50 mg of *T. ammi*, 10 mg of *S. aromaticum*, 100 mg of *A.vasica Nees*, 100 mg of *E hirta*, and 100 mg of *M. koinegii*. per dose.

31. A method as claimed in claim 23, wherein the additives *M. paniculate Linn*, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A.vasica Nees*, *E hirta*, and *M. koinegii* are administered to include properties such as antidiahorial, antiseptic, carminative, stimulation, anti-cough, anti- bronchitis and nourishment.

32. A method as claimed in claim 23, wherein the additives are obtained from : *M. paniculate Linn* (bark or root), *H. abelmoschus* from dried flower buds, *T. ammi* from leaves, *S. aromaticum* from whole plant *A.vasica Nees* from root, *E hirta* from bark, and *M. koinegii* from leaves.

33. An anti-oxidant composition for human beings and animals, said composition comprising a effective amount of extract obtained from the plant *Murraya Koenigii* together with or optionally, associated with pharmaceutically acceptable additives.

34. A composition as claimed in claim 33 wherein additives comprise powder or extracts of plants selected from *M. paniculate Linn*, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A.vasica Nees*, *E hirta*, and *M. koinegii*.

35. A composition as claimed in claim 33, wherein the additives are present in a range of 80-100 mg of *M. paniculate Linn*, 40-60 mg of *H. abelmoschus*, 38-62 mg of *T.ammi*, 7-13 mg of *S. aromaticum*, 85-115 mg of *A.vasica Nees*, 90-110 mg of *E hirta*, and 87-105 mg of *M. koinegii*. per dose.

36. A composition as claimed in claim 33, where in the additives are preferably present in an amount 90 mg of *M. paniculate Linn*, 50 mg of *H. abelmoschus*, 50 mg of *T. ammi*, 10 mg of *S. aromaticum*, 100 mg of *A.vasica Nees*, 100 mg of *E hirta*, and 100 mg of *M. koinegii*. per dose.

37. A composition as claimed in claim 33, wherein the additives *M. paniculate Linn*, *H. abelmoschus, T. ammi, S. aromaticum, A.vasica Nees, E hirta,* and *M. koinegii* are added to provide properties namely, antidiahorial, antiseptic, carminative, stimulation, anti-cough, anti- bronchitis and nourishment, respectively.

38. A composition as claimed in claim 33, wherein the additives are selected from *M. paniculate Linn*, *H. abelmoschus, T. ammi, S. aromaticum, A.vasica Nees, E hirta,* and *M. koinegii* in the form of bark or root; seed; fruit; dried flower buds; leaves; whole plant; and root, bark, leaves, respectively.

39. Use of the extract obtained from the plant *Murraya koinegii* for the treatment of asthma.

40. An anti-asthma agent obtained from the plant *Murraya koinegii.*